{"id":411896,"date":"2025-12-11T00:30:00","date_gmt":"2025-12-10T23:30:00","guid":{"rendered":"https:\/\/medizinonline.com\/new-perspectives-in-first-line-therapy\/"},"modified":"2025-12-10T21:16:04","modified_gmt":"2025-12-10T20:16:04","slug":"new-perspectives-in-first-line-therapy","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/new-perspectives-in-first-line-therapy\/","title":{"rendered":"New perspectives in first-line therapy"},"content":{"rendered":"\n

At this year’s IASLC World Conference on Lung Cancer<\/em> (WCLC 2025) in Barcelona, a poster on the FLAURA2 study was presented, which presented new data on combination therapy with osimertinib in first-line EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). <\/em>The study showed that <\/em>osimertinib in combination with chemotherapy consisting of pemetrexed with cisplatin or carboplatin reduced the risk of death by 23% compared to monotherapy with generally manageable side effects. <\/strong><\/p>\n\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Log in here<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

At this year’s IASLC World Conference on Lung Cancer (WCLC 2025) in Barcelona, a poster on the FLAURA2 study was presented, which presented new data on combination therapy with osimertinib……... <\/p>\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Log in here<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":411901,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Lung cancer with EGFR mutation","footnotes":"[{\"id\":\"e88b0f85-a52c-4cc0-be2c-2e37b16bcaa3\",\"content\":\"www.swissmedic.ch\\\/swissmedic\\\/de\\\/home\\\/humanarzneimittel\\\/authorisations\\\/new-medicines.html<\\\/a>
www.ema.europa.eu\\\/en\\\/documents\\\/overview\\\/tagrisso-epar-medicine-overview_en.pdf<\\\/a>\"}]"},"category":[11513,11370,11455,11548,11503],"tags":[57799,83869,86217,86220,86223,86219,86222],"powerkit_post_featured":[],"class_list":["post-411896","post","type-post","status-publish","format-standard","has-post-thumbnail","category-congress-reports","category-oncology","category-pneumology","category-rx-en","category-studies","tag-carboplatin-en","tag-cisplatin-en","tag-egfrm-nsclc","tag-flaura-2","tag-flaura2","tag-osimertinib-combination-therapy","tag-pemetrexed","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-15 04:34:56","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":411839,"slug":"nouvelles-perspectives-dans-le-traitement-de-premiere-ligne","post_title":"Nouvelles perspectives dans le traitement de premi\u00e8re ligne","href":"https:\/\/medizinonline.com\/fr\/nouvelles-perspectives-dans-le-traitement-de-premiere-ligne\/"},"it_IT":{"locale":"it_IT","id":411894,"slug":"nuove-prospettive-nella-terapia-di-prima-linea","post_title":"Nuove prospettive nella terapia di prima linea","href":"https:\/\/medizinonline.com\/it\/nuove-prospettive-nella-terapia-di-prima-linea\/"},"pt_PT":{"locale":"pt_PT","id":411850,"slug":"novas-perspectivas-na-terapia-de-primeira-linha","post_title":"Novas perspectivas na terapia de primeira linha","href":"https:\/\/medizinonline.com\/pt-pt\/novas-perspectivas-na-terapia-de-primeira-linha\/"},"es_ES":{"locale":"es_ES","id":411846,"slug":"nuevas-perspectivas-en-la-terapia-de-primera-linea","post_title":"Nuevas perspectivas en la terapia de primera l\u00ednea","href":"https:\/\/medizinonline.com\/es\/nuevas-perspectivas-en-la-terapia-de-primera-linea\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/411896","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=411896"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/411896\/revisions"}],"predecessor-version":[{"id":411902,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/411896\/revisions\/411902"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/411901"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=411896"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=411896"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=411896"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=411896"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}